Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

Recruiting

Conditions: Asthma
Atopic Dermatitis (AD)

Interventions: Drug: dupilumab

First Posted Date: 2019-11-22

Last Posted Date: 2023-11-18

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT04173442

Locations: 🇺🇸
Regeneron Research Site, La Jolla, California, United States

REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

Phase 3

Terminated

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: REGN3918

First Posted Date: 2019-11-14

Last Posted Date: 2023-06-12

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT04162470

Locations: 🇬🇧
Regeneron Study Site, Leeds, United Kingdom

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

Phase 2

Completed

Conditions: Generalized Lipodystrophy

Interventions: Drug: Placebo
Drug: Low-Dose REGN4461
Drug: High-dose REGN4461

First Posted Date: 2019-11-12

Last Posted Date: 2024-10-01

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT04159415

Locations: 🇹🇷
Regeneron Research Site, Izmir, Turkey

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Cutaneous Squamous Cell Carcinoma

Interventions: Drug: Cemiplimab

First Posted Date: 2019-11-07

Last Posted Date: 2023-02-08

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 79

Registration Number: NCT04154943

Locations: 🇩🇪
Regeneron Study Site, Tübingen, Germany

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Phase 2

Completed

Conditions: Neovascular (Wet) Age-Related Macular Degeneration

Interventions: Drug: High-dose aflibercept
Drug: aflibercept

First Posted Date: 2019-10-15

Last Posted Date: 2023-08-14

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 106

Registration Number: NCT04126317

Locations: 🇵🇷
Regeneron Study Site, Arecibo, Puerto Rico

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

Phase 3

Completed

Conditions: Retinopathy of Prematurity

Interventions: Drug: aflibercept
Procedure: laser photocoagulation

First Posted Date: 2019-09-24

Last Posted Date: 2023-07-20

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 127

Registration Number: NCT04101721

Locations: 🇻🇳
Regeneron Study Site, Hue, Vietnam

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

Phase 1

Active, not recruiting

Conditions: Relapsed Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: REGN5459

First Posted Date: 2019-09-10

Last Posted Date: 2024-11-07

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT04083534

Locations: 🇺🇸
Regeneron Study Site, Milwaukee, Wisconsin, United States

REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: NSCLC

Interventions: Drug: REGN5093

First Posted Date: 2019-09-04

Last Posted Date: 2024-03-06

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 82

Registration Number: NCT04077099

Locations: 🇰🇷
Regeneron Research Facility, Seoul, Korea, Republic of
🇫🇷
Regeneron Study Site, Caen cedex, France

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Phase 1

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions: Drug: REGN5678
Drug: Cemiplimab

First Posted Date: 2019-06-03

Last Posted Date: 2024-10-30

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 345

Registration Number: NCT03972657

Locations: 🇺🇸
University of Virginia Health Systems - Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States
🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Providence Saint John's Health Center, Santa Monica, California, United States

and more 13 locations

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

Phase 1

Completed

Conditions: Birch Pollen Allergy
Healthy Volunteers

Interventions: Drug: REGN5713-5714-5715
Drug: Matching placebo

First Posted Date: 2019-05-31

Last Posted Date: 2020-04-28

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 96

Registration Number: NCT03969849

Locations: 🇧🇪
Regeneron Study Site, Leuven, Belgium

Home Terms & Conditions Privacy Policy